Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps1-01-01 | COVID & Thyroid Disease | ETA2022

Autoimmune and inflammatory thyroid diseases following SARS-CoV-2 vaccines: an update from a systematic review of the literature

Grunenwald Solange , Caron Philippe

Since the emergence of the Covid-19 pandemic in 2019, a massive vaccination campaign has been undertaken around the world, and SARS-CoV-2 vaccines-induced thyroid diseases became more frequently described in the literature. Subacute thyroiditis is reported in 52 patients, mean age 45.5±1.8 years, mainly in women (n = 39), after the first (62%) or the second (38%) dose of mRNA (60%), inactivated whole-virus (25%) and adenoviral-vectored (13.5%) vaccines. The mean ti...

ea0081p136 | Environmental Endocrinology | ECE2022

Orbital inflammatory disease following mrna sars-cov-2 vaccine: a case report

Solange Grunenwald , Lethellier Gabriel , Imbert Philippe , Dekeister Celine , Caron Philippe

SARS-CoV-2 vaccination campaigns document a satisfactory high profile of protection against Covid-19 infection, but auto-immune/inflammatory diseases have been reported following Covid-19 vaccines. A 65-year-old woman reported two days following her first dose of the BNT162b2 mRNA vaccine tearing, eye irritation, conjunctival redness, peri-orbital swelling, spontaneous hematoma of the right lower eyelid, right greater than left proptosis, with a spontaneous improvement of symp...

ea0063p247 | Pituitary and Neuroendocrinology 1 | ECE2019

MRI follow-up is not useful in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogs (SMSa)

Grandgeorge Naia , Barchetti Giovanni , Grunenwald Solange , Bonneville Fabrice , Caron Philippe

Introduction: Primary SMSa treatment can be associated with hormonal remission and tumor shrinkage in patients with GH-secreting pituitary adenomas. In the 2014 Endocrine Society guideline for Acromegaly, there is no specific mention of MRI follow-up during long-term SMSa treatment. The aim of this study was to evaluate any change of GH-secreting adenoma size during primary SMSa treatment and whether regular MRI follow-up was necessary in acromegalic patients treated with firs...

ea0063p338 | Thyroid 1 | ECE2019

Thyroid-associated orbitopathy and quality of life: correlation of GO-QoL with clinical activity score and severity in 101 patients

Borel Marine , Grunenwald Solange , Imbert Philippe , Dekeister Celine , Caron Philippe

Thyroid-associated orbitopathy (TAO) is a classic and sometimes severe complication of autoimmune process associated with thyroid diseases, more common in GravesÂ’ disease. Due to its functional impairment and disfiguring clinical presentation, TAO affects the quality of life of patients. Few studies have examined the importance of this impact in these patients. The main objective of this retrospective study is to determine if there is a correlation between the deteriorati...

ea0070aep759 | Pituitary and Neuroendocrinology | ECE2020

MRI follow-up of patients with acromegaly treated with first-generation somatostatin analogues (SMSa): Is there a difference during primary or post-operative treatment?

Naia Grandgeorge , Giovanni Barchetti , Solange Grunenwald , Fabrice Bonneville , Caron Philippe

Objectives: First-generation SMSa are the medical treatment of choice in the management of acromegaly, mainly as adjuvant treatment of pituitary surgery when normal IGF-1 is not obtained or as primary treatment in selected patients. The main objective of this study is to evaluate regular pituitary MRI follow-up of acromegalic patients treated with SMSa as adjuvant treatment of pituitary surgery. The secondary objective is to compare the anti-tumoral effect of SMSa in post-oper...

ea0063gp212 | Gestational and Type 1 Diabetes | ECE2019

Prevalence of gestational diabetes during 14 pregnancies of acromegalic women

Vialon Magaly , Grunenwald Solange , Mouly Celine , Vezzosi Delphine , Bennet Antoine , Caron Philippe

Introduction: Abnormalities of glycoregulation are frequent in acromegaly (15-38%) secondary to insulin resistance related to GH/IGF-1 hyper-secretion. The frequency of gestational diabetes (GD) in women with acromegaly was reported in the French multicenter study (JCEM, 2010, 95, 4680) as increased mainly in the absence of pre-gestational control of GH/IGF-1 hyper-secretion. The aim of this study was to evaluate the frequency of GD in a cohort of acromegalic women, and compar...

ea0081p159 | Pituitary and Neuroendocrinology | ECE2022

What is the relevance of he systematic use of gadolinium (Gd) during the MRI follow-up of non-functioning pituitary adenomas (NFPAs)?

Villemaire Axel , Mouly Celine , Solange Grunenwald , Adam Gilles , Darcourt Jean , Patsoura Sofia , Roques Margaux , Catalaa Isabelle , Fayolle Helio , Cognard Christophe , Sol Jean-Christophe , Caron Philippe , Fabrice Bonneville

Objective: To compare the performances of the coronal contrast-enhanced T1-weighted (ceT1-w) and T2-weighted (T2-w) sequences, for the diagnosis of progression during the MRI follow-up of NFPAs.Materials and methods: 106 patients who had at least two MRIs for the follow-up of NFPA were retrospectively included. The largest diameter of the adenomas was measured on coronal ceT1-w and separately on T2-w sequences for all the MRIs of the follow-up, and by 2 ...

ea0070aep665 | Pituitary and Neuroendocrinology | ECE2020

Assessment of disease control in patients with acromegaly treated with long-acting somatostatin analogs (SMSa) varies according to the time when IGF-I levels are measured during the month following the injection

Cristina Albrici , Lecoq Anne-Lise , Vialon Magaly , Solange Grunenwald , Cocco Aldo , Hamdi Safouane , Vincenzo Cimino , Maione Luigi , Caron Philippe , Chanson Philippe

Introduction: Acromegaly is associated with multiple comorbidities and excess mortality. However, disease burden is reduced by maintaining IGF-1 (and/or GH) levels under safe levels. First generation long-acting SMSa, administered at monthly intervals, represent the first line medical treatment. According to guidelines, its efficacy is evaluated through IGF-I measurements. However, there are no data indicating the optimal time for measuring IGF-I levels after the SMSa injectio...